Trials / Conditions / Undifferentiated Pleomorphic Sarcoma

Undifferentiated Pleomorphic Sarcoma

25 registered clinical trials studyying Undifferentiated Pleomorphic Sarcoma — 8 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk T NCT06526897	ECOG-ACRIN Cancer Research Group	N/A
Recruiting	MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma NCT06277154	HRYZ Biotech Co.	Phase 2
Not Yet Recruiting	Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone Sarcomas NCT05515068	Klinikum Stuttgart	—
Recruiting	Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas NCT05182164	Institut Bergonié	Phase 2
Withdrawn	Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma NCT05116800	Brown University	Phase 2
Withdrawn	A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas NCT04906876	Brown University	Phase 2
Recruiting	Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients NCT05961761	Niels Junker	Phase 2
Active Not Recruiting	ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or NCT04480502	Tracon Pharmaceuticals Inc.	Phase 2
Active Not Recruiting	Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma NCT04420975	Jonsson Comprehensive Cancer Center	Phase 1
Recruiting	A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma NCT04332874	Memorial Sloan Kettering Cancer Center	Phase 2
Recruiting	Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sar NCT04055220	Centre Leon Berard	N/A
Recruiting	Focused Ultrasound to Promote Immune Responses for Undifferentiated Pleomorphic Sarcoma NCT04123535	Matthew Bucknor	N/A
Completed	Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas NCT04242238	Memorial Sloan Kettering Cancer Center	Phase 1
Completed	Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma Patie NCT04008238	Institut Bergonié	N/A
Active Not Recruiting	Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma T NCT02923778	National Cancer Institute (NCI)	Phase 2
Terminated	A Study of LY3435151 in Participants With Solid Tumors NCT04099277	Eli Lilly and Company	Phase 1
Unknown	Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated NCT03946943	Di Wu	Phase 2
Completed	A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas NCT03899805	Dana-Farber Cancer Institute	Phase 2
Completed	A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) NCT03752398	Xencor, Inc.	Phase 1
Unknown	Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas NCT03989596	Maria Sklodowska-Curie National Research Institute of Oncology	Phase 2
Completed	CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma NCT03425279	BioAtla, Inc.	Phase 1 / Phase 2
Active Not Recruiting	Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable NCT03307616	M.D. Anderson Cancer Center	Phase 2
Unknown	Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Ex NCT03651375	Maria Sklodowska-Curie National Research Institute of Oncology	Phase 2
Completed	Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma NCT02584309	Washington University School of Medicine	Phase 2
Completed	ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors NCT02565758	AbbVie	Phase 1